125 related articles for article (PubMed ID: 37479061)
21. Comparison of organ-at-risk sparing and plan robustness for spot-scanning proton therapy and volumetric modulated arc photon therapy in head-and-neck cancer.
Barten DL; Tol JP; Dahele M; Slotman BJ; Verbakel WF
Med Phys; 2015 Nov; 42(11):6589-98. PubMed ID: 26520750
[TBL] [Abstract][Full Text] [Related]
22. Physical and Radiobiological Evaluation of Accelerated Intensity Modulated Radiotherapy for Locally Advanced Head and Neck Cancer and Comparison with Short-Term Clinical Outcomes.
Buchapudi RR; Manickam R; M R AK; C R TP; Chandraraj V; Pyakuryal A; Narayanasamy G
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2463-2470. PubMed ID: 31450921
[TBL] [Abstract][Full Text] [Related]
23. Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis.
Jakobi A; Bandurska-Luque A; Stützer K; Haase R; Löck S; Wack LJ; Mönnich D; Thorwarth D; Perez D; Lühr A; Zips D; Krause M; Baumann M; Perrin R; Richter C
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1165-1174. PubMed ID: 26194685
[TBL] [Abstract][Full Text] [Related]
24. Patient selection for proton therapy using Normal Tissue Complication Probability with deep learning dose prediction for oropharyngeal cancer.
Huet-Dastarac M; Michiels S; Rivas ST; Ozan H; Sterpin E; Lee JA; Barragan-Montero A
Med Phys; 2023 Oct; 50(10):6201-6214. PubMed ID: 37140481
[TBL] [Abstract][Full Text] [Related]
25. Development of advanced preselection tools to reduce redundant plan comparisons in model-based selection of head and neck cancer patients for proton therapy.
Tambas M; van der Laan HP; Rutgers W; van den Hoek JGM; Oldehinkel E; Meijer TWH; van der Schaaf A; Scandurra D; Free J; Both S; Steenbakkers RJHM; Langendijk JA
Radiother Oncol; 2021 Jul; 160():61-68. PubMed ID: 33892024
[TBL] [Abstract][Full Text] [Related]
26. Dose planning study of proton versus photon radiotherapy for head and neck squamous cell carcinoma of unknown primary in the primary and recurrent setting.
Holm AIS; Elstrøm UV; Nielsen SB; Jensen K
Acta Oncol; 2023 Nov; 62(11):1412-1417. PubMed ID: 37815913
[TBL] [Abstract][Full Text] [Related]
27. Automated Robust Planning for IMPT in Oropharyngeal Cancer Patients Using Machine Learning.
van Bruggen IG; Huiskes M; de Vette SPM; Holmström M; Langendijk JA; Both S; Kierkels RGJ; Korevaar EW
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1283-1290. PubMed ID: 36535432
[TBL] [Abstract][Full Text] [Related]
28. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort.
Blanchard P; Wong AJ; Gunn GB; Garden AS; Mohamed ASR; Rosenthal DI; Crutison J; Wu R; Zhang X; Zhu XR; Mohan R; Amin MV; Fuller CD; Frank SJ
Radiother Oncol; 2016 Dec; 121(3):381-386. PubMed ID: 27641784
[TBL] [Abstract][Full Text] [Related]
29. Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.
Stokkevåg CH; Indelicato DJ; Herfarth K; Magelssen H; Evensen ME; Ugland M; Nordberg T; Nystad TA; Hægeland C; Alsaker MD; Ulven K; Dale JE; Engeseth GM; Boer CG; Toussaint L; Kornerup JS; Pettersen HES; Brydøy M; Brandal P; Muren LP
Acta Oncol; 2019 Oct; 58(10):1416-1422. PubMed ID: 31364899
[No Abstract] [Full Text] [Related]
30. Introducing Proton Track-End Objectives in Intensity Modulated Proton Therapy Optimization to Reduce Linear Energy Transfer and Relative Biological Effectiveness in Critical Structures.
Traneus E; Ödén J
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):747-757. PubMed ID: 30395906
[TBL] [Abstract][Full Text] [Related]
31. Radiation dose-painting with protons vs. photons for head-and-neck cancer.
Håkansson K; Smulders B; Specht L; Zhu M; Friborg J; Rasmussen JH; Bentzen SM; Vogelius IR
Acta Oncol; 2020 May; 59(5):525-533. PubMed ID: 31964199
[No Abstract] [Full Text] [Related]
32. Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses.
Dutz A; Lühr A; Troost EGC; Agolli L; Bütof R; Valentini C; Baumann M; Vermeren X; Geismar D; Timmermann B; Krause M; Löck S
Radiother Oncol; 2021 Jul; 160():69-77. PubMed ID: 33872640
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of automated proton therapy plan adaptation for head and neck tumors using cone beam CT images.
Kurz C; Nijhuis R; Reiner M; Ganswindt U; Thieke C; Belka C; Parodi K; Landry G
Radiat Oncol; 2016 Apr; 11():64. PubMed ID: 27129305
[TBL] [Abstract][Full Text] [Related]
34. Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients.
van Dijk LV; Steenbakkers RJ; ten Haken B; van der Laan HP; van 't Veld AA; Langendijk JA; Korevaar EW
PLoS One; 2016; 11(3):e0152477. PubMed ID: 27030987
[TBL] [Abstract][Full Text] [Related]
35. Is noncoplanar plan more robust to inter-fractional variations than coplanar plan in treating bilateral HN tumors with pencil-beam scanning proton beams?
Yi B; Jatczak J; Deng W; Poirier YP; Yao W; Witek ME; Molitoris JK; Zakhary MJ; Zhang B; Biswal NC; Ferris MJ; Mossahebi S
J Appl Clin Med Phys; 2024 Feb; 25(2):e14186. PubMed ID: 37974385
[TBL] [Abstract][Full Text] [Related]
36. Organs-at-risk dose and normal tissue complication probability with dynamic trajectory radiotherapy (DTRT) for head and neck cancer.
Bertholet J; Mackeprang PH; Loebner HA; Mueller S; Guyer G; Frei D; Volken W; Elicin O; Aebersold DM; Fix MK; Manser P
Radiother Oncol; 2024 Jun; 195():110237. PubMed ID: 38513960
[TBL] [Abstract][Full Text] [Related]
37. [Proton therapy for head and neck squamous cell carcinomas: From physics to clinic].
Beddok A; Vela A; Calugaru V; Tessonnier T; Kubes J; Dutheil P; Gérard A; Vidal M; Goudjil F; Florescu C; Kammerer E; Bénézery K; Hérault J; Bourhis J; Thariat J;
Cancer Radiother; 2019 Sep; 23(5):439-448. PubMed ID: 31358445
[TBL] [Abstract][Full Text] [Related]
38. Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
Michiels S; Barragán AM; Souris K; Poels K; Crijns W; Lee JA; Sterpin E; Nuyts S; Haustermans K; Depuydt T
Radiother Oncol; 2018 Jul; 128(1):161-166. PubMed ID: 28951008
[TBL] [Abstract][Full Text] [Related]
39. Intensity-modulated proton and carbon-ion radiotherapy using a fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.
Ming X; Mao J; Ma N; Chen J; Wang W; Sheng Y; Wu K
Phys Med Biol; 2024 Jan; 69(1):. PubMed ID: 38064747
[No Abstract] [Full Text] [Related]
40. Patient anatomy-specific trade-offs between sub-clinical disease coverage and normal tissue dose reduction in head-and-neck cancer.
Kaplan LP; Holm AIS; Eriksen JG; Heijmen BJM; Korreman SS; Rossi L
Radiother Oncol; 2023 May; 182():109526. PubMed ID: 36764458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
